#Open journalism No news is bad news

Your contributions will help us continue to deliver the stories that are important to you

Support The Journal
Dublin: 11°C Monday 23 May 2022

New drug slows tumour growth

The company behind the new drug, Afinitor, will file for worldwide regulatory approval this week.

Image: John Birdsall/John Birdsall/Press Association Images

A NEW CANCER drug is said to slow the growth of tumours in advanced breast cancer.

The drug, Afinitor, is made by Swiss company Novartis AG, who said its study of the drug in combination with Pfizer inc’s exemestene in 700 post-menopausal women with advanced breast cancer had finished early after positive results.

This combination of drugs is said to potentially extend the time until chemotherapy is needed for these patients.

The treatment works by inhibiting a protein that can trigger cancer growth and it is expected to become a ‘blockbuster’ drug.

The success of the trials means that the the drug may receive regulatory approval in Europe and the US, where it is already approved for other cancers.

The company is expected to file Afinitor for worldwide regulatory approval this week.

For more information read this story on Nasdaq.com>

Read next: